Mesoblast in potential $1.7bn partnership with Novartis to develop remestemcel-L

Mesoblast (ASX:MSB) has licensed its lead drug candidate to Novartis (NYSE:NVS) in a deal that could be worth as much … Read More

The post Mesoblast in potential $1.7bn partnership with Novartis to develop remestemcel-L appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *